e21510 Background: There is controversy information about efficacy of adjuvant chemotherapy (ACT) for treatment of Soft Tissue Sarcomas (STS) due to histological heterogeneity of these tumors. Whereas STS are heterogeneous group with different sensitivity to chemotherapy (CT), we conducted retrospective study to assess efficacy of adjuvant chemotherapy in patient with high-grade malignant fibrous histiocytoma (MFH). Methods: From 2000 to 2010, 56 patients with localized malignant fibrous histiocytoma were treated in Russian Cancer Research Center named after N.N. Blokhin. Main features: median age 61 years (range: 16–83 years); III stage 37/56, 66%; II stage 19/56, 34%, median tumor size 10cm (range: 2-25 cm); ACT received 18/56, 32%; ACT not received 36/56, 64%; doxorubicin-based CT 16/18, 88%; ifosfamid-based CT 2/18, 12%. Median follow-up was 59 month. Results: Median disease free survival (DFS) was 30 month. Median overall survival (OS) not reached. Median DFS in patients receiving CT was 30 month versus 10 month in patients without CT (p=0.02, HR=2.5; 95% CI 1.09-5.3). In patients with ACT disease progression was observed statistically significantly less often, then without it (39% versus 69%, p=0.04). Three-year OS in patients with ACT was 95% versus 65% in patients control group (p=0.05). We conducted univariate analysis of features, which influence the risk of disease progression disease. Features of favorable prognosis were T1 (p=0.05) and ACT (p=0.04). In multivariate analysis these features remained statistically significant: T (p=0.01, OR 6.7; 95% CI 1.3-34.1), ACT (p=0.02, OR 0.2; 95% CI 0.05-0.7). Conclusions: ACT improved DFS and OS in patients with high-grade localized resectable MFH. These benefits require confirmation in larger studies.
Primary Malignant Fibrous Histiocytoma: A Rare Case